



## NEWS RELEASE

### Teijin and JCR Cease JTR-161 Dental Pulp Stem Cell Research

Tokyo, Japan, April 18, 2022 ---[Teijin Limited](#) (Teijin) and [JCR Pharmaceuticals Co., Ltd.](#) (JCR) announced today that they have decided to terminate their co-development and Japan licensing agreement aimed at developing JTR-161, an allogeneic regenerative medical product containing dental pulp stem cells (DPCs) for the intended purpose of helping patients recover from acute cerebral infarctions (strokes). Using DPC isolated from human teeth extraction bodies, JTR-161 was expected to effectively suppress inflammation through immune regulatory factors and stimulate organ regeneration through trophic factors.

JCR and Teijin signed their agreement in July 2017 and launched Japan-based Phase I/II clinical trials in 2019 to examine the safety and efficacy of intravenously administering JTR-161 to patients who have suffered acute cerebral infarction. The primary endpoint was not achieved, however, so the two companies have decided to terminate their agreement and cease joint development. And Teijin will return its Japan rights to JCR.

JCR works to develop proprietary technologies and innovative products in anticipation of the needs of the times under our corporate philosophy of "Contributing towards people's healthcare through pharmaceutical products." JCR, as a specialty pharma in the rare disease arena, is fully committed to tackling ambitious initiatives in service of its patients worldwide.

Teijin's healthcare business is focused on enhancing the quality of human life to enable people worldwide to enjoy fulfilling lives from birth to their final days. Teijin actively pursues alliances to research and develop medical products that enable patients to benefit from innovative and effective treatments.

#### About JCR Pharmaceuticals

JCR is a biopharmaceutical specialty pharma which is engaged in research, development, manufacture, and market of pharmaceuticals based on regenerative medicine, genetic recombination, and gene therapy technologies that have pioneered the era under our corporate philosophy of "Contributing towards people's healthcare through pharmaceutical products." In the arena of rare diseases, which has been JCR's target since its establishment in 1975, JCR has been working on proprietary technology developments and creation of products in a manner to be "one step ahead" of competitors at all times. JCR aims to create sustainable values for patients with various diseases. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar.

For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

**Investors & Media:**

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

**About the Teijin Group**

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement "Human Chemistry, Human Solutions," Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD 9.5 billion) in the fiscal year that ended on March 31, 2021.

Please visit [www.teijin.com](http://www.teijin.com)

**Press Contact**

Corporate Communications

Teijin Limited

+81 (0)3 3506 4055

[pr@teijin.co.jp](mailto:pr@teijin.co.jp)